CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Loncastuximab Tesirine 用于治疗复发/难治性弥漫性大 B 细胞淋巴瘤
英文原题：Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
查看英文原题
Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
目前，相当大比例的DLBCL患者在一线免疫化疗后难治或复发。自体干细胞移植或CAR-T 细胞治疗后的第二次复发治疗选择很少，且效果不佳。新的分子已进入免疫治疗武器库。Loncastuximab tesirine包含一种人源化抗CD19单克隆偶联抗体，由抗CD19抗体和细胞毒性烷化剂SG3199组成。多项研究已证明其在治疗难治性DLBCL病例中的疗效，且安全性良好，主要不良反应为中性粒细胞减少、血小板减少和肝酶受累。在这篇综述中，我们解释了该分子的作用机制、使其获得FDA批准的临床数据，以及 proposed 与该药物联合的新治疗选择。
展开英文摘要原文
Currently, a significant percentage of patients with DLBCL are refractory or relapse after a first line of immunochemotherapy. Second relapses after autologous stem cell transplantation or chimeric antigen receptor T-cell therapies present few treatment options and do not yield good results. New molecules have entered the immunotherapy arsenal. Loncastuximab tesirine comprises a humanized anti-CD19 monoclonal conjugated antibody, which consists of an anti-CD19 antibody and cytotoxic alkylating agent, SG3199.
Several studies have proven its efficacy in the treatment of refractory cases of DLBCL with a good safety profile, with the main adverse effects being neutropenia, thrombopenia, and liver enzyme involvement. In this review, we explain the mechanism of action of this molecule, the clinical data that have led to its acceptance by the FDA, and the new therapeutic options that are proposed in association with this drug.
论文信息
- 作者
- Juárez-Salcedo LM、Nimkar S、Corazón AM、Dalia S
- 第一作者单位
- Hematology Department, La Princesa University Hospital, 28006 Madrid, Spain.United States
- 通讯作者单位
- Hematology/Oncology Department, Mercy Clinic Oncology and Hematology, Joplin, MI 73120, USA.United States
- 文献类型
- 综述
- 期刊
- International journal of molecular sciences2024 Jul 10
- 原文标识
- PubMed 39062823 · DOI 10.3390/ijms25147580
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →